Biocon Biologics targets top three biosimilar spot: Shreehas Tambe

The opportunity ahead of us is massive because over the next 10 odd years until 2032, we see 55 blockbuster molecules and biologics going out or losing exclusivity, says Tambe

Biocon Biologics bought Viatris’ global biosimilars business last year to become one of the top five global players in the space. The Biocon subsidiary’s managing director and chief executive officer Shreehas Tambe talks about the company’s trajectory in the biosimilar market and key growth drivers in a video interview with Anjali Singh. Edited excerpts:

Biocon Biologics nearly doubled its revenue in the second quarter riding on integration of Viatris’ biosimilar business and the growth in market share in US and Europe. So are you winning new customers in these markets?

Yes, and one of the big things that's helped us